Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3336MR)

This product GTTS-WQ3336MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3336MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5349MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ10103MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ12728MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ13852MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ10676MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ10419MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ13223MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ4662MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW